$LIAN News
Last published 1y ago
- 1y agoTLPHOLMASYNACTMGTX+1Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsPR NewswireAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global...
- 2y agoLIANLianBio Announces Voluntarily Delisting from NasdaqGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and
- 2y agoLIANLianBio Announces Completion of Strategic ReviewGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and
- 2y agoLIANLianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 2y agoLIANLianBio Announces Departure of Chief Financial OfficerGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 2y agoLIANLianBio Announces Departure of Chief Executive OfficerGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 2y agoLIANLianBio's Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra BiosciencesGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 2y agoLIANLianBio Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in
- 3y agoLIANLianBio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireEntered into agreement with Bristol Myers Squibb for mavacamten in China and other Asian marketsPhase 3 data from EXPLORER-CN trial of mavacamten presented in an oral late-breaking science session at the European Society
- 3y agoLIANLianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex BlepharitisGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 3y agoLIANLianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023GlobeNewswireSHANGHAI, China and PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian
- 3y agoLIANLianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian MarketsGlobeNewswireLianBio to receive total upfront consideration of $350 millionLianBio Board of Directors to conduct strategic review of business SHANGHAI and PRINCETON, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN),
- 3y agoLIANLianBio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireMavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic
- 3y agoLIANLianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex BlepharitisGlobeNewswireSHANGHAI, China and PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- LianBio's (NASDAQ:LIAN) partner, Tarsus Pharmaceuticals (Tarsus), announced yesterday that the U.S. Food and Drug Administration (FDA) approved
- 3y agoLIANLianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and ThailandGlobeNewswireSHANGHAI, China and PRINCETON, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 3y agoLIANLianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023GlobeNewswireSHANGHAI, China and PRINCETON, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 3y agoLIANLianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR MutationsGlobeNewswireSHANGHAI, China and PRINCETON, N.J., July 12, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 3y agoLIANLianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in SingaporeGlobeNewswireSHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian markets, today
- 3y agoLIANLianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex BlepharitisGlobeNewswire• LIBRA trial designed to support registration of TP-03 in China• Topline results expected in the fourth quarter of 2023 SHANGHAI, China and PRINCETON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN),
- 3y agoLIANLianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in ChinaGlobeNewswireSHANGHAI, China and PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 3y agoLIANLianBio to Participate in Upcoming Investor ConferencesGlobeNewswireSHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 3y agoLIANLianBio Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpointChina National Medical Products Administration (NMPA) accepted mavacamten New Drug
- 3y agoLIANLianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of ChinaGlobeNewswireSHANGHAI, China and PRINCETON, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 3y agoLIANLianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese PatientsGlobeNewswire• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If
- 3y agoLIANLianBio Promotes Pascal Qian to Chief Commercial OfficerGlobeNewswireSHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets,
- 3y agoLIANLianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic CardiomyopathyGlobeNewswireSHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets,
- 3y agoLIANLianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing, with data expected mid-year 2023 Phase 3 registrational trial of TP-03 in Chinese patients with
- 3y agoLIANPFEPfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and SingaporeGlobeNewswirePfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive a $20 million upfront payment, to be released from previously restricted cash
- 3y agoLIANLianBio Announces President and Chief Strategy Officer DepartureGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 4y agoLIANLianBio Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment completed in registrational Phase 3 EXPLORER-CN trial of mavacamten, with data expected mid-2023Mavacamten patient education and physician awareness activities underway in China with inclusion in HCM treatment
- 4y agoLIANLianBio to Participate in Upcoming Investor and Industry EventsGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 4y agoLIANLianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid TumorsGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today
- 4y agoLIANLianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex BlepharitisGlobeNewswire• LIBRA trial designed to support registration in China• Topline results expected in the fourth quarter of 2023 SHANGHAI and PRINCETON, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a
- 4y agoLIANNBTXNANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck CancerBusiness WireRegional activation for Nanobiotix pivotal Phase 3 trial in head and neck cancer proceeds as planned with first patient enrolled in Asia by partner LianBio The collaboration continues to build momentum behind LianBio's leadership in Asia while Nan
- 4y agoLIANLianBio Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireCompleted enrollment in China Phase 3 trial of mavacamten; topline data expected mid-2023 Submitted mavacamten New Drug Application (NDA) in Singapore Submitted infigratinib NDA in Hong Kong Three additional registration-enabling programs to begi
- 4y agoLIANLianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy PatientsGlobeNewswire• Topline data expected mid-2023 • EXPLORER-CN trial, together with PK study conducted in healthy Chinese volunteers, expected to support registration of mavacamten in China SHANGHAI, China and PRINCETON, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE)
- 4y agoLIANLianBio to Participate in June Investor EventsGlobeNewswireSHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the man
- 4y agoLIANLianBio Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireLianBio's partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients
- 4y agoLIANLianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese VolunteersGlobeNewswireMavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten in obstructive hypertrophic cardiomyopathy to suppo
- 4y agoLIANLianBio to Participate in the Bank of America Securities 2022 Healthcare ConferenceGlobeNewswireSHANGHAI, China and PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that management will p
- 4y agoLIANLianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03 for the Treatment of Demodex BlepharitisGlobeNewswireSHANGHAI, China and PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- LianBio's (NASDAQ:LIAN) partner, Tarsus Pharmaceuticals, Inc. (Tarsus) yesterday announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondar
- 4y agoLIANU.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and SymptomsGlobeNewswireSHANGHAI and PRINCETON, N.J., April 29, 2022 (GLOBE NEWSWIRE) -- LianBio's (NASDAQ:LIAN) partner, Bristol Myers Squibb, announced yesterday that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg and 15 mg
- 4y agoBLBXLIANQNRXREDU+1Thinking about buying stock in Quoin Pharmaceuticals, LianBio, RISE Education, Winc, or Blackboxstocks?PR NewswireNEW YORK, April 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QNRX, LIAN, REDU, WBEV, and BLBX.
- 4y agoLIANLianBio Announces Formation of Scientific Advisory BoardGlobeNewswireSHANGHAI, China and PRINCETON, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the formation and memb
- 4y agoLIANPFELianBio's Partner ReViral Enters into Acquisition Agreement with PfizerGlobeNewswireSHANGHAI AND PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) announced today that its partner, ReViral Ltd., is expected to be acquired by Pfizer Inc. (NYSE:PFE). LianBio has existing collaboration agreements with both compani
- 4y agoLIANLianBio Appoints Wei Wei Chen to Board of DirectorsGlobeNewswireSHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the appointment of Wei Wei Ch
- 4y agoLIANLianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted breakthrough therapy designation in China for the treatment of patients with oHCM Infigratinib
- 4y agoLIANLianBio Issues Statement Regarding the HFCAAGlobeNewswireSHANGHAI and PRINCETON, N.J., March 10, 2022 (GLOBE NEWSWIRE) -- Following the Determination Report of the Public Company Accounting Oversight Board ("PCAOB") issued on December 16, 2021, on March 8, 2022 the U.S. Securities and Exchange Commission (th
- 4y agoLIANLianBio Announces Mavacamten Granted Breakthrough Therapy Designation in ChinaGlobeNewswireSHANGHAI and PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Center for Drug Evalu
- 4y agoLIANLianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic CardiomyopathyGlobeNewswireSHANGHAI, China and PRINCETON, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has b